FDA Approves Foradil Certihaler
LONDON, UK, 18 December 2006 -- SkyePharma PLC announces today that the US Food and Drug Administration (FDA) has approved Foradil Certihaler (formoterol fumarate inhalation powder) for the treatment of asthma. Foradil Certihaler has been co-developed by SkyePharma and Novartis, and is a trademark of Novartis.
The FDA issued an ’approvable’ letter for Foradil Certihaler in April 2006. Following a recall from the German and Swiss markets in January 2006 because of concerns that accidental mishandling of the device may have resulted in inaccurate dosing in a small number of cases. The device was modified and the modifications were submitted to the FDA.
The Foradil Certihaler has been approved in 27 countries outside the USA, and SkyePharma is in discussion with Novartis with respect to commercial launch in these territories.
SkyePharma earns a royalty on sales of Foradil Certihaler in all markets. SkyePharma also manufactures and supplies the Foradil Certihaler.
Frank Condella, CEO, SkyePharma said: ’We are extremely pleased by the FDA’s decision to approve the modifications to Foradil Certihaler. We believe that this approval validates SkyePharma’s inhalation technology and paves the way to future products.’
Source: SkyePharma PLC
Pharma Industry News Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
